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Introduction
Telomeres protect chromosomal ends from replicative attrition 
and consist of tandem repeats of telomeric DNAs and a multi-
protein complex (Greider and Blackburn, 1985, 1996; de Lange, 
2005; Songyang and Liu, 2006). The telomere length plays a 
crucial role in preserving its integrity, and is maintained by the 
telomerase in more than 80% of the human cancers (Greider 
and Blackburn, 1989; Shay et al., 2001). In the other 10–15% of 
human cancers, the telomerase activity is undetectable (Shay 
and Bacchetti, 1997). Those telomerase-inactive cells are known 
as alternative lengthening of telomeres (ALT) cells and are 
thought to use the homologous recombination (HR) mechanism 
for telomere maintenance (Bryan et al., 1995, 1997; Shay 
and Bacchetti, 1997; Liu et al., 2007). One unique feature of 
ALT cells is the formation of the ALT-associated PML body 
(APB; Yeager et al., 1999; Dunham et al., 2000), which requires 
the SUMOylation of TRF1 and TRF2 (Potts and Yu, 2007) and 
several PML-associated proteins, including PML, MRN com-
plex, RAD52, and RPA (Wu et al., 2000; Zhu et al., 2000; Jiang 
et al., 2007). The biological role of APB remains unclear, but 
may be linked to the HR event (Grobelny et al., 2000).
A potential molecule that regulates the telomere integrity 
in cancer and stem cells is nucleostemin (NS). NS is a nucleolar 
GTP-binding protein preferentially expressed by multiple types of 
stem cells and human cancers (Tsai and McKay, 2002; Baddoo 
et al., 2003; Liu et al., 2004; Ohmura et al., 2008; Nomura et al., 
2009; Lin et al., 2010). Its function is required for self-renewal 
maintenance and early embryogenesis (Tsai and McKay, 2002; 
Liu et al., 2004; Beekman et al., 2006; Zhu et al., 2006). We pre-
viously found that NS and its vertebrate paralogue, guanine 
nucleotide-binding protein-like 3-like (GNL3L), interact with 
one of the telomeric proteins, telomeric repeat-binding factor 1 
(TRF1; Zhu et al., 2006, 2009; Tsai, 2009), which serves several 
key functions, including chromosomal end protection (Martínez 
et al., 2009), telomere shortening (van Steensel and de Lange, 
1997), mitotic progression (Zhou et al., 2003, 2009), and APB 
formation (Potts and Yu, 2005; Jiang et al., 2007). Here, we 
report a novel mechanism by which NS prevents TIF (telomere 
dysfunction-induced foci) formation and telomere aberration in 
both ALT and telomerase-active (TA+) cells. NS does so by pro-
moting the association between PML-IV and SUMOylated 
TRF1, which increases the telomeric recruitment of RAD51 pro-
teins. We propose that continuously dividing cells may use NS 
as a protective mechanism to maintain their telomere integrity.
Continuously dividing cells must be protected from telomeric and nontelomeric DNA damage in order to maintain their proliferative potential. Here, we 
report a novel telomere-protecting mechanism regulated 
by nucleostemin (NS). NS depletion increased the number 
of telomere damage foci in both telomerase-active (TA+) 
and alternative lengthening of telomere (ALT) cells and 
decreased the percentage of damaged telomeres associ-
ated with ALT-associated PML bodies (APB) and the number 
of APB in ALT cells. Mechanistically, NS could promote the 
recruitment of PML-IV to SUMOylated TRF1 in TA+ and 
ALT cells. This event was stimulated by DNA damage. 
Supporting the importance of NS and PML-IV in telomere 
protection, we demonstrate that loss of NS or PML-IV 
increased the frequency of telomere damage and aberra-
tion, reduced telomeric length, and perturbed the TRF2BM-
induced telomeric recruitment of RAD51. Conversely, 
overexpression of either NS or PML-IV protected ALT and 
TA+ cells from telomere damage. This work reveals a novel 
mechanism in telomere protection.
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also increases the number of damage foci on interstitial chro-
mosomes (IDF) in both U2OS and HeLa cells. The increase of 
IDF by NS-KD (2.6-fold and 3.5-fold) is less than that of TIF 
(4.7-fold and 4.2-fold) in either cell type.
NS depletion decreases the percentage of 
TIF associated with APB and the formation 
of APB
To investigate the mechanism by which NS depletion triggers 
telomere damage, we chose to study its effect on APB formation, 
as APB was linked to the HR event (Grobelny et al., 2000) and 
NS was shown to interact with an essential component of APB, 
TRF1 (Zhu et al., 2006). First, we used triple-labeled confocal 
analyses to determine whether APBs are associated with TIF 
Results
Loss of NS triggers telomeric and 
nontelomeric DNA damage
We first investigated the effect of NS depletion on the number 
of telomeric (TIF) and nontelomeric (IDF, interstitial damage 
foci) damage foci in ALT (U2OS) and TA+ (HeLa) cells. TIF 
(53BP1+TRF2+) and IDF (53BP1+TRF2) were determined by 
3D-reconstructed confocal analyses. Depletion of NS was 
achieved by the siRNA-mediated knockdown approach, which 
allowed a significant reduction of NS proteins in U2OS and 
HeLa cells (90% or more; Fig. S1, A and B). We found that 
knockdown of NS (NS-KD) by siNS induces a significant increase 
of TIF in both U2OS and HeLa cells (Fig. 1, A and B). NS-KD 
Figure 1. NS depletion triggers telomeric and nontelomeric DNA damage in ALT and TA+ cells, and decreases the formation of APB in ALT cells. (A) Damage 
on the telomere (TIF) and interstitial chromosome (IDF) was detected by the 53BP1+TRF2+ and 53BP1+TRF2 foci, respectively, on 3D-reconstructed confocal 
images. The bottom and right images represent the stacked images along the X-Z and Y-Z axis, respectively. NS knockdown (NS-KD) by siNS increases both 
TIF and IDF in U2OS (ALT) cells. (B) NS-KD also increases TIF and IDF in HeLa (TA+) cells. (C) Transfection of a TRF2-dominant mutant (TRF2-DN, also known 
as TRF2BM) significantly increases the number of TIF and the percentage of TIF associated with APB (PML+53BP1+TRF1-GFP+ over 53BP1+TRF1-GFP+ foci). 
The TRF2-DN–induced increase of APB-occupied TIF is reduced by NS-KD (yellow bars). In contrast, the percentage of undamaged telomeres occupied by 
APB is hardly affected by TRF2-DN transfection or NS-KD (gray bars). (D) NS-KD reduces the formation of APB (TRF2+PML+) in U2OS cells. Y-axis indicates 
the percentage of APB among PML bodies (APB/PML). (E) A nucleoplasmic mutant of NS, NSdB, is distributed predominantly in the nucleoplasm (E1) but 
still retains the ability to bind TRF1 in coIP experiments (E2). Overexpression of wild-type NS or NSdB can both promote the APB formation in U2OS cells (E3). 
Fib, fibrillarin. *, P < 0.01; **, P < 0.001; ***, P < 0.0001. Bars, 5 µm.
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by an E3 ligase, MMS21 (Potts and Yu, 2007), we examined 
how NS and GNL3L affect the interaction between TRF1 and 
MMS21. Coimmunoprecipitation (coIP) showed that the bind-
ing between TRF1 and MMS21 is reduced by GNL3L over-
expression but not affected by NS overexpression (Fig. 2 C). 
As NS and GNL3L display opposite effects on APB formation 
and TRF1 SUMOylation, we tested whether GNL3L depletion 
causes DNA damage, and found that GNL3L knockdown has 
no effect on the formation of TIF or IDF in either ALT or TA+ 
cells (Fig. S2, A and B). These findings suggest that TRF1 
SUMOylation by itself may not be a sufficient determinant to 
explain the TIF-regulatory activity of NS.
To explore the possibility that NS may regulate APB 
formation after the TRF1 SUMOylation step, we designed a 
C-terminally SUMO1-fused TRF1 construct (TRF1-So) to mimic 
the mono-SUMOylated TRF1 protein (Fig. 3 A, left). This 
design is based on a similar strategy used to study p53 monoubiq-
uitination (Carter et al., 2007). The six C-terminal residues on 
the SUMO1 fusion of TRF1-So, including the di-Gly motif, 
were deleted to avoid direct conjugation of TRF1-So to off- 
target proteins. A SUMO-compromised mutant (TRF1R6) was 
also created by mutating the six SUMO-targeting Lys residues 
to Arg, as described in Potts and Yu (2007). TRF1-So and 
TRF1R6 display a higher (51.9%) and a lower (29.0%) per-
centage of APB among PML bodies (APB/PML) than does 
TRF1 (39.6%; P < 0.001), respectively, and may therefore 
mimic the SUMOylated and deSUMOylated states of TRF1 
(Fig. 3 A, right). The APB/PML percentage of a compound 
mutant, TRF1R6-So, resembles that of TRF1-So, suggesting 
that the SUMO conjugate acts dominantly over the R6 mutant. 
We first confirmed that all mutant proteins colocalize with the 
endogenous TRF2 signal at the telomere (Fig. S3). NS knock-
down reduces the APB/PML percentage of TRF1-So from 50.9 
to 42.7% (P < 0.01), and NS overexpression does the opposite 
(67.9%; P < 0.001; Fig. 3 B). In contrast, GNL3L perturbation 
has no effect on the APB/PML percentage of TRF1-So. These re-
sults indicate that the APB- and TIF-regulatory activities of NS 
regulate the recruitment of PML bodies to SUMOylated TRF1, 
whereas the APB activity of GNL3L targets the SUMOylation 
event of TRF1.
induced by TRF2BM transfection in U2OS cells. TRF2BM is 
a TRF2 mutant that triggers telomere damage by destabilizing 
the telomeric complex (van Steensel et al., 1998). We found that 
TRF2BM dramatically increases the percentage of APB-occupied 
TIF (PML+53BP1+TRF1-gfp+ foci divided by 53BP1+TRF1-gfp+ 
foci) from 0.5% to 35.8% (P < 0.0001), but has no effect on the 
percentage of APB-occupied undamaged telomeres (10.7% vs. 
12.3%; P = 0.28; Fig. 1 C). Importantly, knockdown of NS 
reduces the TRF2BM-triggered increase of APB-occupied TIF 
from 35.8% to 23.7% (P < 0.05). These results support a link 
between APB and telomere damage in U2OS cells and suggest 
that NS may have a role in the formation of APB. Indeed, NS-KD 
significantly reduces the percentage of APB (PML+TRF2+) 
among PML bodies from 60.3% to 30.4% (P < 0.0001; Fig. 1 D), 
and NS overexpression shows the opposite effect (Fig. 1, E3). 
To determine whether the nucleolar localization of NS is re-
quired for its APB-regulatory function, we measured the effect 
of a nucleoplasmic mutant of NS, NSdB, which is deleted of its 
nucleolar localization signal (NoLS, aa 1–46) at the N terminus 
(Meng et al., 2006). NSdB is distributed predominantly in the 
nucleoplasm (Fig. 1, E1), but still retains the ability to bind TRF1 
(Fig. 1, E2). Compared with the wild-type NS, NSdB shows a 
similar but stronger effect in promoting the formation of APB in 
U2OS cells (Fig. 1, E3), indicating that the telomere function of 
NS takes place outside the nucleolus. These results suggest that 
NS may prevent telomere damage by stimulating the formation of 
APB in ALT cells. Because NS perturbation does not change the 
number of PML bodies, TRF2 foci, or TRF1-gfp foci (Fig. S1, 
C and D), we reason that NS may increase APB by promoting 
the association between telomeres and PML bodies.
NS promotes PML body recruitment  
to SUMOylated TRF1
Because APB formation requires SUMOylation on TRF1 (Potts 
and Yu, 2007), we next determined whether NS regulates TRF1 
SUMOylation. Our results showed that NS overexpression 
increases TRF1 SUMOylation and NS knockdown does the 
opposite (Fig. 2, A and B). Interestingly, GNL3L perturbation 
shows the opposite effects on TRF1 SUMOylation compared 
with NS perturbation. Because TRF1 SUMOylation is catalyzed 
Figure 2. TRF1 SUMOylation is increased by NS and reduced by GNL3L. (A) The amount of SUMOylated TRF1 in the pull-down fraction (His PD) is 
increased by NS overexpression and decreased by GNL3L overexpression. (B) Conversely, NS-KD (shNS) decreases TRF1 SUMOylation, whereas 
GNL3L knockdown (shG3L) shows the opposite effect. (C) The coIP efficiency of TRF1 and MMS21 is reduced by GNL3L overexpression but not affected 
by NS overexpression.
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We found that TRF1-So interacts strongly with PML-IV (X63131) 
but not with PML-III (S50913) or PML-VI (M80185; Fig. 3 C, 
left). TRF1 itself shows a detectable but much weaker bind-
ing to PML-IV compared with TRF1-So (Fig. 3 C, right; and 
Fig. S4 A). A PML-IV-specific siRNA was synthesized that 
NS promotes the interaction between 
SUMOylated TRF1 and PML-IV
To determine the molecular event mediating the association 
between PML bodies and SUMOylated TRF1, we performed coIP 
of TRF1-So and different PML isoforms (Jensen et al., 2001). 
Figure 3. NS promotes the colocalization of PML bodies and SUMOylated TRF1 foci and the binding between PML-IV and SUMOylated TRF1 proteins. 
(A) A SUMO-conjugated TRF1 (TRF1-So) was created by fusing SUMO1 to the C terminus of TRF1 (left). The SUMO1 fusion was deleted of its six C-terminal 
residues, including the di-Gly motif indicated by the X-mark. SUMO-compromised TRF1 constructs were created by mutating six Lys residues to Arg on TRF1 
(TRF1R6) or TRF1-So (TRF1R6-So). Respectively, TRF1-So and TRF1R6 mutants mimic the SUMOylated and deSUMOylated state of TRF1 in their abilities to 
form APB in U2OS cells (right). (B) The percentage of APB among PML bodies (APB/PML) of TRF1-So is decreased by NS-KD (shNS) and increased by NS 
overexpression (NS-OE), but not affected by GNL3L perturbation. (C) CoIP of FLAG-tagged TRF1 (or TRF1-So) and Myc-tagged PML (III, IV, or VI) reveals a 
specific interaction between PML-IV and TRF1-So. (D) Real-time RT-PCR confirms the knockdown efficiency of PML-IV–specific siRNA (siPML4) on the PML-IV 
transcript but not on the PML-I transcript in U2OS cells. (E) Knockdown of PML-IV decreases the APB/PML percentage of U2OS cells from 60.3% to 46.1% 
without changing the total number of PML bodies. (F) Knockdown and overexpression experiments showed that NS plays a role in promoting the binding 
between SUMOylated TRF1 and PML-IV. (G) PML-IV knockdown completely abolishes the NS-dependent increase of APB formation of SUMOylated TRF1. 
(H) TRF2-DN–triggered telomere damage induces APB formation in HeLa (TA+) cells. This increase is significantly attenuated by depletion of NS 
or PML-IV.
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can knock down more than 60% of the PML-IV transcript with-
out affecting PML-I, which shares the most sequence identity 
with PML-IV (Fig. 3 D). Supporting the role of PML-IV in 
APB regulation, PML-IV knockdown decreases the APB/PML 
percentage from 60.3 to 46.1% (P < 0.001) without changing 
the total number of PML bodies per cell (P = 0.60; Fig. 3 E). In 
addition, NS overexpression significantly increases the binding 
between TRF1-So and PML-IV (Fig. 3 F, left), and NS knock-
down does the opposite (Fig. 3 F, right). For control experiments, 
we confirmed that NS interacts with TRF1 and TRF1-So equally 
well (Fig. S4 B) but not with PML-IV (Fig. S4 C), and excluded 
the possibility that NS and PML-IV bind TRF1-So through its 
C-terminal SUMO-1 fusion (Fig. S4 D). Furthermore, the NS 
ability to promote the association between SUMOylated TRF1 
(TRF1-So) and PML bodies is completely abolished by knock-
down of PML-IV (P < 0.001; Fig. 3 G). As APB is a hallmark 
of ALT cells, it is unclear whether this NS-regulated recruit-
ment of PML bodies to the telomere occurs in TA+ cells. To 
address this issue, we examined the formation of APB in HeLa 
cells (Fig. 3 H). HeLa cells contain few APBs under normal 
conditions (7.9% of total PML), but show a significant increase 
of APBs under the TRF2BM-induced telomere damage condition 
(34.6%; P < 0.0001). Notably, knockdown of NS or PML-IV 
reduces the TRF2BM-triggered APB formation to 23.8 and 
19.5%, respectively. These results demonstrate that NS promotes 
the telomeric recruitment of PML bodies by increasing the 
association between SUMOylated TRF1 and PML-IV in both 
ALT and TA+ cells.
DNA damage increases the interaction 
between SUMOylated TRF1 and PML-IV  
in an NS-dependent manner
Because TA+ cells show APB formation only under the TRF2BM-
transfected condition, we asked whether DNA damage increases 
the recruitment of PML bodies to SUMOylated TRF1 foci in 
an NS-dependent manner in U2OS cells. DNA damage was 
induced by etoposide, which is a topoisomerase II inhibitor 
capable of inducing telomeric and nontelomeric DNA damage 
(Yoon et al., 1998; Zhang et al., 2003; Kang et al., 2004). We 
showed that etoposide can significantly increase the APB/PML 
percentage of TRF1-So from 51.9 to 83.6% (P < 0.001), and 
that NS-KD abolishes most of this effect (61.2%; Fig. 4 A). 
CoIP showed that both TRF2BM-induced telomere damage 
and etoposide-induced DNA damage increase TRF1-So binding 
to PML-IV (Fig. 4 B), and that etoposide treatment increases 
the interaction between NS and TRF1-So (Fig. 4 C). Importantly, 
the increased binding between PML-IV and TRF1-So after 
etoposide treatment is abrogated by NS-KD (Fig. 4 D). To deter-
mine the interaction between native NS and TRF1 proteins 
under normal and DNA damage conditions, we performed 
endogenous coIP experiments in HeLa cells. The results con-
firmed that the endogenous NS and TRF1 proteins bind each 
other under the undamaged condition and that their interaction 
is increased by etoposide treatment (Fig. 4 E). Similarly, bind-
ing between endogenous TRF1 and PML proteins is signifi-
cantly increased under the DNA damage condition (Fig. 4 F). 
More importantly, a high molecular weight product of TRF1 
(73 kD) is co-purified with PML proteins under the DNA 
damage condition. This same product is recognized by the anti–
SUMO-1 antibody and hence represents the SUMOylated form 
of TRF1. The ratio of SUMOylated-to-non-SUMOylated TRF1 
proteins is significantly greater in the pull-down fraction than 
in the input lysate, indicating that PML binding enriches for 
the SUMOylated form of TRF1. These results support that DNA 
damage increases the interaction between SUMOylated TRF1 
and PML proteins.
Loss of PML-IV or NS increases the 
frequency of telomere damage  
and aberration
To demonstrate the importance of PML-IV in reducing telo-
mere damage, we showed that loss of PML-IV in U2OS cells 
increases the number of TIF per cell by threefold (from 0.17 to 
0.50; P < 0.01) and IDF by 2.4-fold (from 1.2 to 2.9; P < 0.01; 
Fig. 5 A). In HeLa cells, PML-IV depletion also increases the 
number of TIF (from 0.17 to 0.54; P < 0.01) and IDF (from 
0.49 to 1.24; P < 0.001; Fig. 5 B). To establish the biological 
significance of NS and PML-IV in maintaining the telomere 
integrity, we measured their knockdown effects on telomere 
abnormalities in U2OS cells by telomere fluorescence in situ 
hybridization (Tel-FISH). Tel-FISH showed that loss of NS 
increases the frequency of chromosomes with low telomere 
signals (from 27.2 to 42.3%; P < 0.0001) and the frequency 
of chromosomal fusion (from 3.1 to 5.9%; P < 0.001; Fig. 5 C). 
More than 90% of the increased chromosomal fusion occurs 
between sister chromatids. Similarly, PML-IV depletion in-
creases the frequency of chromosomes with low telomere sig-
nals (44.5%; P < 0.0001) but has no effect on the chromosomal 
fusion event. Low telomere signals indicate that the telomere 
length is decreased. Quantitative FISH (Q-FISH) analyses 
showed that the average telomere intensities of NS-KD and 
PML-KD U2OS cells are significantly lower than that of 
control cells (Fig. 5 D). These data demonstrate the effect of 
PML-IV knockdown in causing telomeric and nontelomeric 
DNA damage and the roles of NS and PML-IV in maintaining 
the telomere integrity.
NS and PML-IV promotes the telomeric 
recruitment of RAD51 induced by  
telomere damage
RAD51 is the core protein in the HR-based repair of damaged 
telomeres (Kibe et al., 2003; Carneiro et al., 2010). To deter-
mine whether NS or PML-IV regulates the recruitment of 
RAD51 to the telomere under the telomere damage condition, 
U2OS cells were transfected with TRF2BM and measured for 
the colocalized RAD51 and TRF1-GFP signals. The results 
showed that the number of telomere-associated RAD51 foci is 
greatly increased by TRF2BM-induced telomere damage 
(from 0.7 to 2.7 per cell; P < 0.0001), and that knockdown of 
NS or PML-IV reduces the frequency of this event (1.7 and 1.5 
per cell; P < 0.01; Fig. 6 A, left). Conversely, overexpression of 
NS or PML-IV under the telomere damage condition increases 
the telomere recruitment of RAD51 from 2.7 to 3.4 (P < 0.001) 
and 6.0 per cell (P < 0.0001), respectively (Fig. 6 B, left). 
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we used the cross-link coIP approach to delineate the binding 
relationship between RAD51 and TRF1-So. Cross-link coIP 
showed that PML-IV is required for the specific interaction 
between RAD51 (FLAG) and TRF1-So (HA), and that this 
interaction is increased by TRF2BM-induced telomere dam-
age (Fig. 6 C, lanes 1–5). By contrast, PML-IV binds RAD51 
directly and independently of telomere damage (Fig. 6 D). 
These results support that NS promotes the association be-
tween RAD51-bound PML-IV and SUMOylated TRF1, and 
that this mechanism is activated by telomere damage.
NS and PML-IV protect ALT and TA+ cells 
from telomere damage
To demonstrate the function of NS and PML-IV in protecting 
against telomere damage, we measured the effect of NS or 
PML-IV overexpression on the formation of TRF2BM-induced 
TIF. First, we confirmed that TRF2BM transfection signifi-
cantly increases the amount of TIF in both U2OS (Fig. 7 A) 
and HeLa cells (Fig. 7 B). In TRF2BM-transfected U2OS 
cells, overexpression of NS reduces the number of TIF from 
As NS knockdown increases nontelomeric RAD51 foci (P < 0.001; 
Fig. 6 A, right) and NS overexpression reduces them (P < 
0.0001; Fig. 6 B, right), we reason that the NS function is to 
promote the telomeric recruitment of RAD51. On the other 
hand, overexpression of PML-IV increases telomeric RAD51 
foci without reducing the number of nontelomeric RAD51 foci 
(Fig. 6 B), which suggests that overexpression of PML-IV may 
increase the formation of RAD51 foci. We confirmed this idea 
by showing that overexpression of PML-IV alone significantly 
increases the formation of RAD51 foci without triggering 
DNA damage, and that all RAD51 foci colocalize with PML-IV 
signals (Fig. S5), which suggests that PML-IV may directly 
interact with RAD51.
The interaction between RAD51 and TRF1-So or PML-IV 
was further investigated by coIP experiments. Regular coIP 
showed a direct interaction between PML-IV and RAD51 but 
a very weak binding between TRF1-So and RAD51, with or 
without PML-IV (unpublished data). The lack of binding be-
tween TRF1-So and RAD51 in regular coIP suggests that 
this event may be transient and highly regulated. Therefore, 
Figure 4. NS mediates DNA damage–increased interaction between PML-IV and SUMOylated TRF1. (A) The APB/PML percentage of TRF1-So foci is 
increased by etoposide (Etop) treatment (from 51.9% to 83.6%). NS-KD abolishes most of the etoposide-induced APB increase (61.2%). (B) CoIP dem-
onstrated that the interaction between PML-IV and TRF1-So is increased by TRF2-DN–induced telomere damage (left) or etoposide-induced DNA damage 
(right). (C) Etoposide treatment also increases TRF1-So binding to NS. (D) NS-KD (shNS) significantly reduces the etoposide-increased interaction between 
PML-IV and TRF1-So. (E) Endogenous coIP results confirmed that the native NS and TRF1 proteins bind each other under the undamaged condition. The 
interaction between these two proteins is increased by etoposide treatment. (F) Immunoprecipitation of endogenous PML proteins by mouse anti-PML anti-
body (PG-M3) coprecipitates only a minimal amount of TRF1 under the normal condition (lane 2). Under the DNA damage condition, a significant amount 
of endogenous TRF1 proteins is copurified with PML proteins (lane 3). A high molecular weight product of TRF1 is copurified with PML proteins only under 
the DNA damage condition. The same TRF1 product can be recognized by the anti–SUMO-1 antibody on the same blot (open arrows). Open arrowheads 
and asterisks mark IgG (H+L) and SUMO-modified proteins copurified with PML proteins, respectively.
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wild-type NS in U2OS cells. To determine whether PML-IV 
is also involved in the nontelomeric DNA damage induced 
by NS-KD, we used PML-IV to rescue the DNA damage 
phenotype of NS-KD cells (Fig. 7 D). Our results showed that 
PML-IV is able to partially rescue the telomeric and nontelo-
meric DNA damage induced by NS-KD in both TA+ and ALT 
cells. These findings indicate that the NS-regulated TRF1–
PML-IV pathway protects both TA+ and ALT cells from telo-
mere damage.
4.3 to 1.8 per cell (P < 0.0001; Fig. 7 A). Overexpression 
of PML-IV in TRF2BM-transfected U2OS cells shows the 
same effect (TIF = 1.9 per cell; P < 0.0001). In TRF2BM-
transfected HeLa cells, overexpression of NS or PML-IV de-
creases the number of TIF from 2.1 to 0.9 and 0.7 per cell, 
respectively (P < 0.001; Fig. 7 B). Notably, the nucleoplasmic 
mutant of NS, NSdB, is also capable of protecting against 
TRF2BM-induced telomere damage in U2OS and HeLa cells 
(Fig. 7 C). This activity of NSdB is even stronger than that of 
Figure 5. Loss of PML-IV or NS increases the frequency of telomere damage and abnormalities. Knockdown of PML-IV by siPML4 increases both TIF 
(53BP1+TRF2+) and IDF (53BP1+TRF2) in U2OS (A) and in HeLa cells (B). (C) The effect of NS and PML-IV knockdown on the telomere integrity was 
determined by telomere fluorescence in situ hybridization (Tel-FISH), which showed that loss of NS increases the frequency of chromosomes with low 
telomere signals (Low-TS, arrows) from 27.2% to 42.3% and chromosomal fusion (asterisks) from 3.1% to 5.9%, but has no clear effect on the number 
of chromosomes with multi-telomeric signals (Multi-TS, M). PML-IV knockdown also increases the frequency of Low-TS chromosomes (44.5%) but does not 
change the frequency of fusion or Multi-TS event. (D) The telomere length distributions of control (gray), NS-knockdown (green), and PML-IV-knockdown 
(red) cells were analyzed by Q-FISH. X-axis represents the telomere signal intensity (in arbitrary units). Y-axis indicates the frequency of event. The aver-
age telomere intensity (mean) and number of telomeres analyzed (n) were shown. Asterisks in A–C represent P values (see Fig. 1). Bars: (A and B) 5 µm; 
(C, large panels) 10 µm; (C, small panels) 5 µm.
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that APB may serve the function of sequestering low molecular 
weight telomeric DNAs, as APB contains linear extrachromo-
somal telomere repeat DNA (Fasching et al., 2007). Others sug-
gested that APB may be linked to the HR function based on its 
content of DNA damage response and repair proteins and its 
DNA synthesis activity (Yeager et al., 1999; Wu et al., 2000, 
2003; Nabetani et al., 2004). We found that TRF2BM-induced 
telomere damage increases the percentage of APB-occupied 
TIF but not the percentage of APB-occupied undamaged telo-
meres, and that NS knockdown reduces the percentage of 
APB-occupied TIF. These findings suggest a link between APB 
and telomere damage and a role of NS in APB formation. 
Indeed, NS can increase APB by promoting the association 
between telomeres and PML bodies. To define the molecular 
interaction between telomeres and PML bodies, we discovered 
a specific binding between PML-IV and SUMOylated TRF1, 
which can be increased by NS and DNA damage signals. Be-
cause PML-IV interacts much more strongly with SUMO-
modified TRF1 than with wild-type TRF1 and does not bind 
NS directly, we propose that NS binding and SUMOylation of 
TRF1 may trigger a conformational change that favors its asso-
ciation with PML-IV, which then brings PML-IV–tethered pro-
teins (e.g., RAD51) to the telomere under damage conditions 
(Fig. 7 E). The activity of NS to promote APB formation in 
U2OS cells or to protect against TRF2BM-induced telomere 
damage in U2OS or HeLa cells does not require its nucleolar 
localization. In fact, the NSdB mutant performs even more effi-
ciently than the wild-type NS in promoting APB or reducing 
TIF in U2OS cells, indicating that the telomere function of NS 
takes place outside the nucleolus. In conjunction with our pre-
vious results showing that the NS protein is not recruited to the 
Discussion
NS protects ALT and TA+ cells from 
telomere damage
In this study, we report the NS function in maintaining the 
integrity of telomeric and interstitial chromosomes and deter-
mine the mechanism underlying the telomere-protecting activ-
ity of NS. Even though loss of NS triggers DNA damage on 
both telomeric and interstitial chromosomes, the NS-KD effect 
is more notable on the telomere than on the nontelomeric chro-
mosome. The NS role in preventing TIF formation is supported 
by the findings that NS knockdown triggers spontaneous telo-
mere damage, NS overexpression protects against TRF2BM-
induced telomere damage, NS depletion reduces the telomere 
length, and loss of NS increases the frequency of chromosomes 
with low telomere signals and sister chromatid fusion. Because 
NS is most abundantly expressed in cancer and stem cells, such 
a mechanism may allow these cells to quickly respond to and 
repair telomere damage in order to maintain their self-renewing 
proliferation. Telomere elongation in embryonic and adult stem 
cells is normally attributed to the telomerase activity, which 
alone may not be sufficient over time. Our discovery suggests the 
possibility that self-renewing cells may be equipped with the 
NS machinery to safeguard their telomere integrity during 
the aging process.
NS promotes the association of 
SUMOylated TRF1 and PML-IV
Our mechanistic investigation on the TIF-regulatory activity of 
NS was based on its ability to bind TRF1 and increase APB for-
mation. APB is a known feature of ALT cells. It was postulated 
Figure 6. NS and PML-IV promote telomeric recruitment of RAD51 under the telomere damage condition. (A) Telomeric recruitment of RAD51 was de-
termined by confocal colocalization of TRF1-GFP and endogenous RAD51 foci. The number of telomere-associated RAD51 foci is increased by TRF2-DN 
transfection (from 0.7 to 2.7 per cell). Knockdown of NS or PML-IV significantly reduces the telomeric recruitment of RAD51 induced by TRF2-DN transfection 
(1.7 and 1.5 per cell, respectively). Both NS and PML-IV knockdown increase the number of nontelomeric RAD51 foci. Asterisks represent P values (see 
Fig. 1). (B) Overexpression of NS or PML-IV increases the number of telomere-associated RAD51 foci. Non-telomeric RAD51 foci are decreased by NS 
overexpression but unchanged by PML-IV overexpression. (C) CoIP confirms that PML-IV mediates the interaction between RAD51 and TRF1-So (lanes 1–4) 
and that this interaction is enhanced by TRF2-DN–induced telomere damage (lane 5). By comparison, PML-IV shows a much weaker effect in mediating the 
binding between RAD51 and TRF1 (lane 6). (D) PML-IV binds RAD51 directly and independently of telomere damage.
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signals, only NS-KD increases the frequency of chromosomal 
fusion, which raises the possibility that PML-IV may not be 
the sole mediator for this NS activity. Based on the lack of 
TRF1 binding by PML-VI and a previous finding that nar-
rows down the TRF1-interactive domain of PML-IV to its 
C-terminal 154 residues (Yu et al., 2010), one may deduce 
that TRF1 binding involves the C-terminal 81 residues of 
PML-IV. Because 84% of this region is found in PML-I, it is 
possible that PML-I may also interact with SUMOylated TRF1 
and play a redundant or complementary role as compared 
with PML-IV.
The ALT-related activity of NS in TA+ cells 
and on interstitial chromosomes
As NS knockdown triggers spontaneous DNA damage not only 
on the telomere of ALT cells but also on the telomere of TA+ 
telomere (Meng et al., 2011), we propose that the NS-mediated 
regulation on the interaction between TRF1 and PML occurs 
in the nucleoplasm and extra-chromosomally before they are 
incorporated into stable large protein complexes on the telomere.
The role of PML-IV in mediating the telomere-protecting 
function of NS is supported by the knockdown experiments, 
which show that loss of PML-IV produces the same TIF phe-
notypes as NS-KD does, and that overexpression of PML-IV 
or NS can protect against TRF2BM-induced telomere dam-
age. In addition, PML-IV is required for the NS-induced asso-
ciation of PML bodies and SUMOylated TRF1 foci, as well 
as the telomeric recruitment of RAD51 under the telomere 
damage condition. More importantly, overexpression of PML-IV 
is able to rescue the telomere damage phenotype of NS-KD in 
both TA+ and ALT cells. Whereas loss of NS or PML-IV both 
show increased numbers of chromosomes with low telomere 
Figure 7. NS and PML-IV protect both ALT and TA+ cells from TRF2-DN–induced telomere damage. Overexpression of NS or PML-IV protects U2OS cells 
(A) and HeLa cells (B) from TRF2-DN–induced TIF without affecting the total number of TRF1-GFP foci. (C) Compared with wild-type NS (NS-WT), the nucleo-
plasmic mutant of NS (NSdB) shows a stronger or similar activity in reducing TRF2-DN–induced TIF in U2OS and HeLa cells, respectively. (D) PML-IV can 
rescue the NS-KD–induced telomere (TIF) and nontelomeric (IDF) damage in U2OS and HeLa cells. (E) A proposed model for the NS function in protecting 
ALT and TA+ cells from telomere damage via the recruitment of RAD51-bound PML-IV to SUMOylated TRF1. Bars, 5 µm.
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5-GAACTAAAACAGCAGCAGA-3; siG3L, 5-AAACGCAGGACCATTG-
AGA-3; siPML4, 5-TGACAATGAAAGTGGGTTC-3; shScr, 5-TCTCG-
CTTGGGCGAGAGTAAG-3; shNS, 5-CCTGATATTAAGCCATCAAAT-3; 
shG3L, 5-CCAATCGAGAGGCTGAATTAA-3.
Immunofluorescence and confocal quantification of TIF, APB,  
and RAD51 foci
TIF were determined by the colocalization of 53BP1 and TRF2 (or TRF1-
GFP) signals. The number of APBs was scored on the basis of colocalized 
PML and TRF2 (TRF1-GFP, or FLAG-tagged TRF1) signals. To detect RAD51 
foci, cells were incubated with the permeabilization solution (10 mM 
Hepes, 100 mM NaCl, 3 mM MgCl2, 300 mM sucrose, and 0.5% Triton) 
for 2 min on ice before the fixation step. Images were acquired on a confo-
cal microscope (LSM510; Carl Zeiss) using a 63x Plan Apochromat oil 
objective (1.4 NA) at room temperature. Scanning was set with a 512 x 512 
frame size, 3x zoom, and <1.0-µm optical thickness. Stacked images of 
80–100 randomly chosen cells were collected at 0.5-µm intervals from five 
independent experiments and analyzed using ImageJ 1.36b software 
(National Institutes of Health, Bethesda, MD).
In vivo SUMOylation assay
His-tagged SUMO-1 and TRF1 expression plasmids were coexpressed in 
HEK293 cells. 2 d later, protein lysates were extracted in 6M guanidinium 
buffer, pulled down by Ni2+-chelating Sepharose in 3 h, and washed care-
fully to prevent degradation of SUMOylated products.
Coimmunoprecipitation
For regular coIP experiments, protein lysates were extracted in NTEN buffer 
without cross-linking. For coIP of TRF1-So and RAD51, protein complexes 
were cross-linked with 1% formaldehyde in PBS for 20 min at 4°C and 
incubated with 125 mM glycine in PBS before the extraction step. Protein 
extracts were precleared by microcentrifugation and incubated with primary 
antibody and protein G–Sepharose (GE Healthcare) for 4 h at 4°C. Immuno-
precipitates were washed extensively before SDS-PAGE. For endogenous 
coIP experiments, the NS and PML protein complexes were immunoprecipi-
tated in HeLa cells by anti-NS (Ab138) or anti-PML (PG-M3) antibody, re-
spectively. Precipitated NS and PML proteins were immunodetected by the 
Ab2438 or H-238 antibody, respectively.
Telomere fluorescence in situ hybridization (T-FISH)  
and quantitative-FISH (Q-FISH)
Cells were treated with colcemid (0.1 µg/ml) for 16 h, incubated in hypo-
tonic solution (0.8% sodium citrate), and fixed in methanol/acetic acid 
(3:1) before spreading onto slides. The T-FISH procedure was conducted 
by incubating metaphase-spread chromosomes with a Cy3-conjugated 
telomere-specific peptide nucleic acid (PNA) probe, (C3TA2)2, in hybridi-
zation buffer (70% formamide, 10 mM Tris, pH 7.2) for 3 h at 25°C and 
counterstaining the chromosomes with TO-PRO-3 dyes. High-resolution 
stacked images were taken on the LSM510 confocal imaging platform 
(Carl Zeiss) using the 63x Plan Apochromat oil objective, and quantified 
for the frequency of telomere aberration on each metaphase-spread chro-
mosome. The relative telomere length was measured by Q-FISH, where indi-
vidual telomere signal intensities of T-FISH were scored using the ImageJ 
telomeric plug-in program.
Online supplemental material
Fig. S1 shows experiments for the siNS-mediated knockdown efficiency and 
the effect of NS perturbation on TRF2 foci and PML bodies. Fig. S2 shows that 
loss of GNL3L does not predispose ALT or TA+ cells to telomere or DNA dam-
age. Fig. S3 shows that GFP- and FLAG-tagged TRF1 proteins colocalize with 
the endogenous TRF2. Fig. S4 shows control experiments for the binding 
specificity between TRF1, PML-IV, NS, and/or GNL3L. Fig. S5 shows that 
overexpression of PML-IV promotes Rad51 foci formation without increasing 
DNA damage. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201109038/DC1.
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cells and on the interstitial chromosome of both TA+ and ALT 
cells, it raises the question of whether the proposed mechanism 
of NS (i.e., the telomeric recruitment of PML-IV) works in TA+ 
cells or on nontelomeric chromosomes. Two lines of evidence 
support that this mechanism is also in use in TA+ cells. First, in 
both ALT and TA+ cells, loss of PML-IV induces telomere dam-
age and overexpression of PML-IV rescues the telomere damage 
effect of NS-KD. Second, APB can be induced by TRF2BM-
triggered telomere damage in HeLa (TA+) cells, and knockdown 
of NS or PML-IV significantly decreases the frequency of this 
event. On the issue of telomeric versus nontelomeric damage, 
the knockdown and rescue results, too, support the involvement 
of PML-IV in alleviating nontelomeric DNA damage.
NS and GNL3L differentially regulate  
APB and TIF
Our data demonstrate that NS and GNL3L exert opposite effects 
on TRF1 SUMOylation. Given that NS and GNL3L compete 
against each other for TRF1 binding (Meng et al., 2011), this 
TRF1 SUMOylation effect of NS may be explained by its abil-
ity to displace TRF1-bound GNL3L. On the other hand, only 
NS but not GNL3L can regulate the association between PML 
and SUMOylated TRF1. It is noted that even though GNL3L 
shows the opposite effect on APB regulation (Zhu et al., 2009) 
and TRF1 SUMOylation compared with NS, it does not exhibit 
the activity to regulate TIF formation as does NS. Therefore, 
TRF1 SUMOylation alone may not be sufficient to explain the 
TIF-regulatory function of NS. Furthermore, the differential 
activities of NS and GNL3L in APB and TIF regulation also 
suggest that APB may be heterogeneous. Not all of them are 
connected to telomere repair. Evolutionarily, NS and GNL3L 
share the same invertebrate orthologue, GNL3 (Tsai and Meng, 
2009). The functional divergence of NS and GNL3L may signify 
an expansion in the telomere-regulatory modality during verte-
brate evolution. Whereas NS extends the proliferative lifespan 
by providing damaged telomeres a better access to repair proteins, 
GNL3L may serve the role of stabilizing the telomere structure 
in differentiated cells.
Materials and methods
cDNA constructs and antibodies
Point mutation and fusion of TRF1 were introduced by the stitching PCR 
strategy (Tsai and McKay, 2005). TRF2BM includes amino acids 45–454. 
Epitope-tagged expression constructs of PML isoforms were made by clon-
ing cDNA fragments PCR amplified from the original PML constructs into the 
Myc- or FLAG-tagged vector. Primary antibodies include anti-HA (HA.11; 
Covance), Myc (9E10; Covance), FLAG (M2; Sigma-Aldrich), TRF1 (TRF-
78; Santa Cruz Biotechnology, Inc.), TRF2 (4A794; EMD), PML (PG-M3, 
H-238; Santa Cruz Biotechnology, Inc.), 53BP1 (4937; Cell Signaling 
Technology), RAD51 (51RAD01; Thermo Fisher Scientific), SUMO-1 (FL-101; 
Santa Cruz Biotechnology, Inc.), and NS (Ab2438 and Ab138). Secondary 
antibodies are conjugated to Rhodamine-X, FITC, or peroxidase.
siRNA knockdown
Knockdown was done by transfecting cells with shRNAmir constructs or 
siRNA duplexes using the Lipofectamine Plus or Oligofectamine reagent, 
respectively. The sequences targeted by the control (siScr), NS-specific (siNS), 
GNL3L-specific (siG3L), and siPML-IV-specific (siPML4) siRNA duplexes, as 
well as the control (shScr), NS-specific (shNS), and GNL3L-specific (shG3L) 
shRNAmir are as follows. siScr, 5-TGACGATCAGAATGCGACT-3; siNS, 
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